Comparing Atrion (ATRI) & Its Competitors

Atrion (NASDAQ: ATRI) is one of 80 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its peers? We will compare Atrion to similar businesses based on the strength of its analyst recommendations, valuation, earnings, institutional ownership, dividends, profitability and risk.

Dividends

Atrion pays an annual dividend of $4.80 per share and has a dividend yield of 0.8%. Atrion pays out 26.6% of its earnings in the form of a dividend. As a group, “Medical Equipment, Supplies & Distribution” companies pay a dividend yield of 1.0% and pay out 42.4% of their earnings in the form of a dividend. Atrion has raised its dividend for 15 consecutive years.

Risk & Volatility

Atrion has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Atrion’s peers have a beta of 1.08, indicating that their average stock price is 8% more volatile than the S&P 500.

Profitability

This table compares Atrion and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atrion 22.98% 18.34% 16.33%
Atrion Competitors -432.83% -26.62% -11.70%

Analyst Ratings

This is a summary of current ratings and recommmendations for Atrion and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atrion 0 0 0 0 N/A
Atrion Competitors 269 1281 2766 91 2.61

As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.61%. Given Atrion’s peers higher possible upside, analysts clearly believe Atrion has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares Atrion and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Atrion $143.49 million $27.58 million 32.37
Atrion Competitors $975.11 million $120.37 million 283.99

Atrion’s peers have higher revenue and earnings than Atrion. Atrion is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

59.0% of Atrion shares are held by institutional investors. Comparatively, 65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 23.1% of Atrion shares are held by company insiders. Comparatively, 12.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Atrion peers beat Atrion on 7 of the 12 factors compared.

About Atrion

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply